Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia

American Journal of Health-System Pharmacy

Volumn 64, Issue 6, 2007, Pages 595-605

  McKenney, James M ^a,b   Sica, Domenic ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b National Clinical Research Inc   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acids, fatty; Coronary disease; Fish oils; Hypertriglyceridemia; Toxicity

Indexed keywords

AMINOCAPROIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SATURATED FATTY ACID; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; BACKACHE; BLEEDING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; ERUCTATION; FLU LIKE SYNDROME; HUMAN; HYPERTRIGLYCERIDEMIA; INFECTION; ISCHEMIC HEART DISEASE; PAIN; PRESCRIPTION; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; TASTE AVERSION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33947601804     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060164     Document Type: Review

References (42)

1. Pronova Biocare. Press release: Omacor approved for treatment. http://hydro.no/en/press_room/news/archive/2001_03/omacor_approved_en.html (accessed 2006 Feb 11).
2. Omacor (omega-3-acid ethyl esters) package insert. Liberty Corner, NJ: Reliant Pharmaceuticals; 2005 Apr.
3. Data on file. Reliant Pharmaceuticals; Liberty Corner, NJ.
4. Oh R. Practical applications of fish oil (ω-3 fatty acids) in primary care. J Am Board Fam Pract. 2005; 18:28-36.
5. Jump DB. Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci. 2004; 41:41-78.
6. Sampath H, Ntambi JM. Polyunsaturated fatty acid regulation of gene expression. Nutr Rev. 2004; 62:333-9.
7. Bezard J, Blond JP, Bernard A et al. The metabolism and availability of essential fatty acids in animal and human tissues. Reprod Nutr Dev. 1994; 34:539-68.
8. Balk E, Chung M, Lichtenstein A et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evidence, report/technology assessment no. 93. (Prepared by the Tufts-New England Medical Center Evidence-based Practice Center, Boston, MA.) Rockville, MD: Agency for Healthcare Research and Quality, 2004; AHRQ publication no. 04-E0102.
9. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002; 106:2747-57.
10. Burdge G. α-Linolenic acid metabolism in men and women: nutritional and biological implications. Curr Opin Clin Nutr Metab Care. 2004; 7:137-44.
11. Miller M. Why triglycerides need to be aggressively managed: a guide for physicians. Cardiovasc Rev Rep. 2003; 24:520-6.
12. Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr. 1997;65(suppl):1687S-98S.
13. Connor WE. n-3 Fatty acids from fish and fish oil: panacea or nostrum? Am J Clin Nutr. 2001;74:415-6.
14. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res. 1989; 30:785-807.
15. Studer M, Briel M, Leimenstoll B et al. Effect of different antilipidemic agents and diets on mortality. Arch Intern Med. 2005; 165:725-30.
16. Agren JJ, Vajsanen S, Hanninen O et al. Hemostatic factors and platelet aggregation after fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids. 1997; 57:419-21.
17. Bucher HC, Hengstler R, Schindler C et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002; 112:298-304.
18. Harris WS. Are omega-3 fatty acids the most important nutritional modulators of coronary heart disease risk? Curr Atheroscler Rep. 2004; 6:447-52.
19. National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002; 106:3143-421.
20. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidiol. 2006; 17:387-93.
21. Rustan AC, Nossen JO, Christiansen EN et al. Eicosapentaenoic acid reduces hepatic synthesis and secretion of triacylglycerol by decreasing the activity of acyl-coenzyme A:1,2-diacylglycerol acyltransferase. J Lipid Res. 1988; 29:1417-26.
22. Marsh JB, Topping DL, Nestel PJ. Comparative effects of dietary fish oil and carbohydrate on plasma lipids and hepatic activities of phosphatidate phosphohydrolase, diacylglycerol acyltransferase and neutral lipase activities in the rat. Biochimica Biophysica Acta. 1987; 922:239-43.
23. Lee SS, Chan WY, Lo CK et al. Requirement of PPARα in maintaining phospholipid and triacylglycerol homeostasis during energy deprivation. J Lipid Res. 2004; 45:2025-37.
24. Chan DC, Watts GF, Mori TA et al. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr. 2003; 77:300-7.
25. Harris WS, Ginsberg HN, Arunakul N et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997; 4:385-91.
26. Pownall HJ, Brauchi D, Kilinc C et al. Correlation of serum triglyceride and its reduction by (ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999; 143:285-97.
27. Borthwick L. The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin Drug Invest. 1998; 15:397-404.
28. Mackness MI, Bhatnagar D, Durrington PN et al. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr. 1994; 48:859-65.
29. Calabresi L, Donati D, Pazzucconi F et al. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis. 2000; 148:387-96.
30. Grundt H, Nilsen DW, Aarsland T et al. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidemia. J Intern Med. 1995; 237:249-59.
31. Chan DC, Watts GF, Barrett HR et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002; 51:2377-86,
32. Durrington PN, Bhatnagar D, Mackness MI et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridemia. Heart. 2001; 85:544-8.
33. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999; 354:447-55.
34. Marchioli R, Barzi F, Bomba E et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione trial. Circulation. 2002; 105:1897-903.
35. Vanschoonbeek K, Feijge AH, Paquay M et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol. 2004; 24:1734-40.
36. Bender NK, Kraynak MA, Chiquette E et al. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis. 1998;5:257-61.
37. U.S. Food and Drug Administration. Federal Register. January 2004. www. fda.gov/ohrms/dockets/95s0316/ 95s-0316-Rpt0272-40-Appendix-D-Reference-F-FDA- vol205.pdf (accessed 2006 Feb 28).
38. Chang JT, Staffa JA, Parks M et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Safety. 2004; 13:417-26.
39. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol. 2004; 94:935-8.
40. McKenney JM. Dyslipidemias, atherosclerosis, and coronary heart disease. In: Koda-Kimble MA, Yoang LY, Kradjan WA et al., eds. Applied therapeutics: the clinical use of drugs. 8th ed. Philadelphia: Lippincott Williams Wilkins; 2005.
41. Krauss RM, Eckel RH, Howard B et al. AHA dietary guidelines. Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000; 102:2284-99.
42. U.S. Department of Agriculture, Agricultural Research Service. 2005. USDA National Nutrient Database for Standard Reference, Release 18. Nutrient Data Laboratory home page. www.ars.usda.gov/ba/bhnrc/ndl (accessed 2006 Dec 28).